The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.
Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.
Frequency Therapeutics is an early-stage developer of small molecule drugs to activate “progenitor cells” and restore healthy tissue. Its lead program is in treating hearing loss by regenerating sensory cells in the inner ear, for which it is planning a Phase 1 trial to launch in mid-2018.
To heal the wounds — maintaining and restoring cellular homeostasis with novel secretomes.
An anti-infective immunotherapy developer on a mission to replace antibiotics with engineered antibodies and novel mechanisms.
In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.
There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.
On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance
There is an obvious, timely issue with Catabasis that deserves observation but should not eclipse the whole of the company — its Phase 2 candidate for treating DMD.
Dr. Leah Makley, president and CSO, founded ViewPoint based on five years of research she conducted in the lab of cofounder Dr. Jason Gestwicki, where all work is dedicated to protein misfolding, primarily in neurodegenerative diseases such as Alzheimer’s.